A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 4, 2009, Pages 402-408

  Avihingsanon, A ^a   Van Der Lugt, J ^a,b   Kerr, S J ^a,c   Gorowara, M ^a   Chanmano, S ^a   Ohata, P ^a   Lange, J ^b   Cooper, D A ^c   Phanuphak, P ^a   Burger, D M ^d   Ruxrungtham, K ^a,e  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b International Antiretroviral Trial Evaluation Centre   (Netherlands)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; LAMIVUDINE; RITONAVIR; TENOFOVIR DISOPROXIL; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; ASIAN; BILIRUBIN BLOOD LEVEL; BODY MASS; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; ETHNIC GROUP; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LOW DRUG DOSE; MALE; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; THAILAND; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; VIRUS LOAD;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; RITONAVIR; THAILAND;

EID: 62649107112     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.244     Document Type: Article

References (33)

1. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services: Bethesda, MD, 2008 〈http://www.aidsinfo.nih. gov〉. Accessed 5 May 2008.
2. Hammer, S.M. et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296, 827-843 (2006).
3. Swainston Harrison, T. & Scott, L.J. Atazanavir: a review of its use in the management of HIV infection. Drugs 65, 2309-2336 (2005).
4. Havlir, D.V. & O'Marro, S.D. Atazanavir: new option for treatment of HIV infection. Clin. Infect. Dis. 38, 1599-1604 (2004).
5. Goldsmith, D.R. & Perry, C.M. Atazanavir. Drugs 63, 1679-1693; discussion 1694-1695 (2003).
6. Colonno, R., Rose, R., McLaren, C., Thiry, A., Parkin, N. & Friborg, J. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J. Infect. Dis. 189, 1802-1810 (2004).
7. Le Tiec, C., Barrail, A., Goujard, C. & Taburet, A.M. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin. Pharmacokinet. 44, 1035-1050 (2005).
8. Perloff, E.S., Duan, S.X., Skolnik, P.R., Greenblatt, D.J. & von Moltke, L.L. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab. Dispos. 33, 764-770 (2005).
9. Zhang, D. et al. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab. Dispos. 33, 1729-1739 (2005).
10. Winston, A. et al. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. J. Antimicrob. Chemother. 56, 380-387 (2005).
11. Colombo, S. et al. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 50, 3801-3808 (2006).
12. Smith, D.E., Jeganathan, S. & Ray, J. Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations. HIV Clin. Trials 7, 34-38 (2006).
13. Huang, S.M. & Temple, R. Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. Clin. Pharmacol. Ther. 84, 287-294 (2008).
14. Ng, P.C., Zhao, Q., Levy, S., Strausberg, R.L. & Venter, J.C. Individual genomes instead of race for personalized medicine. Clin. Pharmacol. Ther. 84, 306-309 (2008).
15. Peck, C.C. & Cross, J.T. "Getting the dose right": facts, a blueprint, and encouragements. Clin. Pharmacol. Ther. 82, 12-14 (2007).
16. Boyd, M. et al. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. Antivir. Ther. 10, 301-307 (2005).
17. Autar, R.S. et al. Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients. J. Antimicrob. Chemother. 56, 908-913 (2005).
18. van der Lugt, J. et al. Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults. J. Antimicrob. Chemother. 61, 1145-1153 (2008).
19. Chetchotisakd, P. & Anunnatsiri, S. Low-dose, once-daily atazanavir/ritonavir (200/100): an effective treatment for HIV-infected patients in Thailand. J. Acquir. Immune Defic. Syndr. 49, 230-231 (2008).
20. Gong, Y.F. et al. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob. Agents Chemother. 44, 2319-2326 (2000).
21. Description of EC50 and conversion to estimated protein adjusted EC90 for atazanavir. BMS Document Control No 930004360 (Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 2003).
22. Zhu, L. et al. CASTLE study: pharmacokinetics and inhibitory quotient of atazanavir/ritonavir 300/100 mg once daily compared to lopinavir/ritonavir 400/100 mg twice daily, each in combination with fixed dose tenofovir-emtricitabine once daily, are supportive of 48 week efficacy and safety in HIV-1 infected, treatment-naive subjects. 9th International Workshop on Pharmacology of HIV Therapy, New Orleans, LA, 7-9 April 2008. Abstract 023.
23. Burger, D.M., Agarwala, S., Child, M., Been-Tiktak, A., Wang, Y. & Bertz, R. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrob. Agents Chemother. 50, 3336-3342 (2006).
24. Reyataz (atazanavir sulfate) capsule [prescribing information (online)]. New York: Bristol-Myers Squibb Company, 2008 〈http://www.bms.com〉. Accessed 29 April 2008.
25. von Hentig, N. et al. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults. Eur. J. Clin. Pharmacol. 63, 935-940 (2007).
26. Optimizing TDM in HIV clinical care: updated guidelines. 7th International Workshop on Clinical Pharmacology of HIV Therapy, Lisbon, Portugal, 20-22 April 2006 〈http://www.hivpharmacology.com〉. Accessed 29 September 2008.
27. Autar, R.S. et al. Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily. J. Antimicrob. Chemother. 54, 785-790 (2004).
28. Ananworanich, J. et al. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients. Antivir. Ther. 10, 761-767 (2005).
29. von Hentig, N. et al. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related cofactors. J. Antimicrob. Chemother. 62, 579-582 (2008).
30. Rodríguez-Nóvoa, S. et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 21, 41-46 (2007).
31. McLean, A.J. & Le Couteur, D.G. Aging biology and geriatric clinical pharmacology. Pharmacol. Rev. 56, 163-184 (2004).
32. Taburet, A.M. et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 48:2091-2096 (2004).
33. Myrand, S.P. et al. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin. Pharmacol. Ther. 2008, 84: 347-361.